2 of the Best Dividend Stocks to Buy With $5,000 in November

Nov 18, 2026
2-of-the-best-dividend-stocks-to-buy-with-$5,000-in-november

Prosper Junior Bakiny, The Motley Fool

6 min read

Investors with different goals and preferences will gravitate toward different companies, even if they have the same investment strategy. That’s why it’s so hard to come up with “the best” of any category of stocks. But we can still give it a try. Consider the following two companies: Johnson & Johnson (NYSE:JNJ) and Walmart (NASDAQ:WMT). Both are longtime market leaders with excellent dividend programs and are arguably among the top income stocks, given their impressive track records.

For those with $5,000 to spare (make sure it isn’t set aside for emergencies), Johnson & Johnson and Walmart are two of the first dividend stocks I’d recommend buying this month. Here is why.

Missed AI’s “Act 1”? Act 2 Could Be 16x Bigger. Most investors think they missed the AI boat because they didn’t buy Nvidia in 2005. But according to our analysts, we’re only at the end of “Act 1″—the R&D phase. “Act 2” is the global rollout. Continue »

Seedlings grow from rising stacks of coins beside a watering can and piggy bank, symbolizing savings growth.

Image source: Getty Images.

1. Johnson & Johnson

Johnson & Johnson has shown its resilience this year. Despite macroeconomic problems, a major U.S. patent cliff it experienced last year, and several of its medicines being targeted by government-led drug price negotiations, the healthcare giant has performed well. Third-quarter revenue increased by 5.9% year over year to $25.4 billion.

Johnson & Johnson’s adjusted earnings per share declined 7.5% year over year to $2.59, primarily due to acquisition-related expenses. Overall, the business is healthy, and Johnson & Johnson once again increased its guidance for the full fiscal year 2026. The company now expects operational sales of $100.7 billion at the midpoint, representing a 6.9% year-over-year increase, versus midpoint sales and year-over-year growth of $100.6 billion and 6.8% year-over-year for its previous guidance.

Johnson & Johnson has also made meaningful clinical and regulatory progress this year, which should help the company boost sales and navigate patent cliffs over the medium term. In March, the company earned approval for Icotyde, a medicine for plaque psoriasis. It has had an impressive commercial ramp-up so far. As management noted, more than 20,000 patients have initiated treatment with Icotyde so far.

The company believes this drug can generate more than $5 billion in peak annual sales. And it boasts several other brand-new approvals or pipeline candidates that it believes can approach or even exceed the $5 billion annual sales milestone. We haven’t even mentioned Johnson & Johnson’s medtech business, where it has also made progress this year.

Leave a comment